Introduction
============

As the most common neurodegenerative disease, Alzheimer\'s disease (AD) has the characteristics of gradual learning and memory process loss, as well as spatial abilities, confusion and altered disorientation. The etiology of AD has been assumed to be neurodegeneration as amyloid precursor protein (APP), in the form of abnormal process, makes peptide A to be produced, aggregated and deposited. It is marked by the senile plaque formation and the death of neuronals ([@b1-etm-0-0-7124]).

The non-cognitive symptoms, behavioral and psychological symptoms of dementia (BPSD) are usually related to AD, with perception, thought content, mood, and behavior disorders included. According to a study, 70--90% of patients with dementia in the progression of the disease will appear to have BPSD within a certain period of time ([@b2-etm-0-0-7124]), which contributes the most to hospitalization and life quality deterioration for patients with AD, and seriously increases family and caregiver burden ([@b3-etm-0-0-7124],[@b4-etm-0-0-7124]). Results from South Korea have pointed out that caregivers\' psychological distress mainly comes from BPSD when they are taking care of patients with dementia, and for the registered nurses and care workers, the most frequent distressing symptom is agitation/aggression. This indicates that it is necessary to assist mitigate caregivers\' burden by improving BPSD treatments ([@b5-etm-0-0-7124]).

In recent years, many studies have focused on identifying treatments for BPSD ([@b6-etm-0-0-7124],[@b7-etm-0-0-7124]). Non-pharmacological interventions should come first, and then the medication, but unfortunately, pharmacological interventions need to be combined for most patients with AD. It is very challenging to treat BPSD due to the severe adverse events in dementia patients, which along with the pharmacological interventions cause limitation of time and quantity. Also, this may put patients at risk due to the shortage of licensed drugs used to treat these symptoms, as well as other optional drugs.

As a moderate-affinity uncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptor, memantine is the first non-cholinergic agent allowed for the treatment of AD in the USA and Europe, and is also the first medication approved to treat the disease from moderate to severe stages. Although it has been proven that memantine is efficient and safe in the treatment of dementia ([@b8-etm-0-0-7124],[@b9-etm-0-0-7124]), it can only slow down the disease process and has also certain defects in controlling BPSD, especially in the initial stage of treatment.

Antipsychotics have been used to treat AD patients\' psychosis, aggression and agitation for a long time, but little progress has been shown due to adverse effects. The new atypical antipsychotics are considered effective medicines that cause fewer adverse effects. The use of atypical antipsychotics, as evaluated by clinical trials, has produced various results without clarity. Many studies have shown that atypical antipsychotics such as risperidone, olanzapine and quetiapine are significant in the treatment of behavioral disturbances and are well tolerated ([@b10-etm-0-0-7124],[@b11-etm-0-0-7124]). Studies have indicated that, despite the concerns about safety, risperidone is still been taken as a popular therapeutic choice among AD patients with psychosis ([@b12-etm-0-0-7124]--[@b14-etm-0-0-7124]). On the contrary, there are many studies indicating that olanzapine, quetiapine, or risperidone do not differ from placebo for treating BPSD ([@b15-etm-0-0-7124]--[@b17-etm-0-0-7124]). USA Food and Drug Administration (FDA) does not allow the use of atypical antipsychotics among the elderly with dementia due to the increased risk of death and serious cardiovascular events in this age group. In fact, because there is no alternative medicine, atypical antipsychotics are still used as first-line therapy for BPSD due to their favorable effect profile.

Serotonergic dysfunction has a connection with the agitation of AD patients and early clinical trial findings have shown that a suitable approach for this is SSRIs ([@b18-etm-0-0-7124]--[@b20-etm-0-0-7124]). Currently there are many studies on antidepressants from the perspective of treatment for agitation and psychosis in dementia ([@b21-etm-0-0-7124]--[@b25-etm-0-0-7124]). A meta-study has shown that compared with placebo, typical and atypical antipsychotics there is a relation between the SSRIs sertraline and citalopram, and the reduction in the symptoms of agitation, which appears to be reasonably well-tolerated compared to placebo and SSRIs. Citalopram as a typical representative of SSRIs is more practical because of its high ability of 5-HT re-uptake, low affinity to the receptors for acetylcholine, histamine, norepinephrine, no accumulation after long-term treatment and a small effect on the cytochrome P450 enzyme system. In a recent study, citalopram in Alzheimer\'s Disease (CitAD), was shown to have a positive effect on the treatment of AD agitation ([@b22-etm-0-0-7124]--[@b25-etm-0-0-7124]).

Our study assessed the effect, safety and tolerability of memantine combined with citalopram in patients with moderate AD with BPSD. The efficacy of memantine combined with citalopram on all BPSD, rather than agitation, was also evaluated. At the same time, we also examined the effects of memantine combined with citalopram on cognitive function and caregiver distress.

Patients and methods
====================

### Subjects

Participants were selected from both the Outpatient and Inpatient Departments of Qingdao Mental Health Center (Qingdao, China) between April 2015 and January 2016. Eighty AD patients with BPSD were enrolled. According to the AD baseline made by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), all subjects enrolled met the criteria. Each patient had a CDR score of 2, and each AD patient had at least one behavioral and psychological symptom, whose diagnosis was provided by psychiatrists. Patients were excluded under the following circumstances: age \>80 years; development of dementia in other forms such as vascular, frontotemporal, and Lewy body; receive of acetylcholinesterase inhibitor including donepezil, huperzine, rivastigmine, or antipsychotic drugs; patients with severe heart disease, arrhythmia, especially QT interval prolongation; and patients with moderate or severe renal failure.

Two groups were established among eligible patients at random. In one group, patients were treated with memantine combined with citalopram, while in the other group, patients were treated wth memantine combined with placebo. The target dose of memantine was 20 mg/day in both groups. The dose of citalopram was designed as 30 mg/day and a single dose was provided in the morning. A dose of 10 mg/day in the beginning was titrated up to 30 mg/day over 2 weeks, and then it could be decreased to 10--20 mg/day depending on tolerability.

The study was approved by the Ethics Committee of Qingdao Mental Health Center and implemented by the guidance of the Declaration of Helsinki. The patients and/or guardians signed an informed consent.

Assessment
----------

### Cognitive assessment

With a rating scale consisting of 11 questions and a total score of 30 points, Mini-Mental State Examination (MMSE) scoring system was applied to assess the severity of cognitive impairment. Dementia patients were distinguished from healthy subjects by three cut-off values. Scores \<17 points were rated as illiteracte; scores \>20 points were rated as primary school; while scores \>24 points were rated as more than high school.

### BPSD assessment

The Neuropsychiatric Inventory (NPI) was employed to assess BPSD. NPI is most widely used in the assessment of dementia-related behavioral symptoms. It is able to examine behavioral functioning in 12 sub-domains which include delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity, night-time behavioral disturbances as well as appetite and eating abnormalities ([@b26-etm-0-0-7124],[@b27-etm-0-0-7124]). NPI was administered to the caregivers of dementia patients and screening questions were asked about each sub-domain. Every caregiver was only asked of all the questions related to the domain in which the patient showed particular problems. The scores were rated on the basis of the frequency of the symptoms on a 4-point scale, a 3-point scale for the severity, and a 5-point scale for the distress caused by the symptoms.

### Safety and tolerability assessment

Blood routine, urine routine, biochemical tests, electrocardiogram and electroencephalogram were done for each patient every month routinely to check the change induced by using medication. Treatment Emergent Symptom Scale (TESS) was used to assess side-effects every 2 weeks.

TESS was developed by NIMH in the United States (1973). It includes not only common adverse symptoms and signs, but also a number of laboratory test results. The advantage of this scale is that the symptoms of each system can be fully identified.

### Statistical analysis

The data entries and subsequent analyses were based on SPSS 18.0 (SPSS, Inc., Chicago, IL, USA). t-test and appropriate Chi-square test were applied for the statistical analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General information

[Table I](#tI-etm-0-0-7124){ref-type="table"} shows demographic, clinical characteristics and assessment results of the patients in the two groups. Distinct differences did not exist concerning sex, age, and education background (P\>0.05); neither concerning the MMSE and NPI scores between the two groups at baseline (P\>0.05).

### Comparison of the change of MMSE and NPI scores

Marked differences existed in the change of MMSE scores between the two groups after treatment (t=3.026, P\<0.05). Patients who received memantine combined with citalopram improved dramatically in the aspect of cognitive function, in comparison to those who received memantine with placebo.

The scores of agitation/aggression, irritability/lability, behavioral disturbances overnight, caregiver distress and NPI total score after treatment decreased quickly compared to those before treatment in both groups (P\<0.05). The scores of apathy, dysphoria, anxiety were far less than those before treatment in patients who received memantine combined with citalopram (P\<0.05). Patients who received memantine combined with citalopram showed statistically significant reduction of total NPI, agitation/aggression, apathy, dysphoria, anxiety and caregiver distress scores compared with those who received memantine with placebo (P\<0.05). Obvious distinction was not found in the change of the scores of delusions, hallucinations, euphoria, disinhibitions, irritability/lability, aberrant motor activity, behavioral disturbances overnight, as well as appetite and eating abnormalities (P\>0.05) ([Table II](#tII-etm-0-0-7124){ref-type="table"}).

### Comparison of the adverse events

The adverse events that most frequently appeared in the study were headache (7.5 vs. 10%), nausea (5 vs. 10%), dizziness (5 vs. 7.5%) and fatigue (2.5 vs. 5%) ([Table III](#tIII-etm-0-0-7124){ref-type="table"}). In addition, there were 2 patients who complained of dry mouth in the study group and there was 1 patient that showed increased libido in the control group and withdrew from the study. QTc interval prolongation was observed in 2 patients who were treated with 30 mg/day citalopram, one of whom withdrew from the study. The two groups had a similar discontinuation caused by adverse events.

Discussion
==========

As a non-cholinergic agent, memantine is the earliest approved for the treatment of moderate to severe AD. The results of recent studies have shown that citalopram affects the treatment of agitation in patients with AD ([@b22-etm-0-0-7124]--[@b25-etm-0-0-7124]). Based on the above research, this study aimed to evaluate the potential of memantine combined with citalopram to ameliorate BPSD and improve cognitive function. It is a clinical trial developed on two parallel treatment groups characterized as randomized, double-masked, placebo-controlled, and is designed according to the advice given by the CitAD Research Group ([@b28-etm-0-0-7124]). A previous study had found that there should be at least a duration of 9 weeks to assure enough time for full response in the treatment with citalopram for agitation in AD ([@b29-etm-0-0-7124]). Since it is important for the clinical trials to have sufficient time, we evaluated the efficacy on cognition and BPSD after 12 weeks.

The first important finding was that there was a significant decrease in the scores of agitation/aggression, irritability/lability, night-time behavioral disturbances, caregiver distress and NPI total score after treatment in the two groups. This result suggests that memantine alone or memantine combined with citalopram can improve agitation/aggression, irritability/lability and night-time behavioral disturbances and reduce caregiver distress.

The results also showed that apathy, dysphoria and anxiety had scores much lower than those before treatment among patients who received memantine combined with citalopram. Citalopram as an antidepressant, can improve depression, dysphoria and anxiety. To our surprise, the results also suggested that citalopram could improve apathy.

A previous study showed that AD patients with severe apathy restarted to eat and increased their intake of fluid after intravenous citalopram, which also supported a certain degree of efficacy of citalopram for apathy ([@b30-etm-0-0-7124]). Moreover, the results revealed that there was a significant difference of the score changes of agitation/aggression before and after treatment between the two groups, which suggested that memantine combined with citalopram can more effectively improve agitation/aggression. Agitation was related to low serotonin (5-HT) and many clinical studies have shown that citalopram can effectively improve agitation ([@b22-etm-0-0-7124]--[@b25-etm-0-0-7124]). Our result was similar to previous studies. In addition, the latest studies have indicated that serotonin signaling has a positive effect on β-amyloid burden and citalopram can reduce AD plaque, the major component of β-amyloid formation, which might be the reason why citalopram can reduce agitation ([@b31-etm-0-0-7124]--[@b34-etm-0-0-7124]). Comprehensive results from NPI showed that memantine combined with citalopram treatment lead to a reduction of total NPI, agitation, apathy, dysphoria, anxiety and caregiver distress scores in AD patients.

In this study, AD patients who received memantine combined with citalopram showed a distinct improvement of cognitive function in comparison to those who received memantine with placebo, which was different from previous research results. Previous researches have found that MMSE results indicate greater cognitive decline with citalopram ([@b22-etm-0-0-7124],[@b24-etm-0-0-7124]). The reasons for the compatability of citalopram to improve the cognitive function may include the following aspects. First, animal experiments have found that the use of SSRI drugs could promote the regeneration of hippocampal nerve to improve memory function ([@b35-etm-0-0-7124]). Second, evidence has shown that citalopram could reduce β-amyloid formation which could cause rapid disrupting of synaptic plasticity and memory impairment ([@b31-etm-0-0-7124]--[@b34-etm-0-0-7124],[@b36-etm-0-0-7124]). Third, antidepressant-induced increase in BDNF levels could reduce neurotoxicity ([@b35-etm-0-0-7124],[@b37-etm-0-0-7124],[@b38-etm-0-0-7124]). Fourth, antidepressant could protect tau from hyperphosphorylation ([@b39-etm-0-0-7124],[@b40-etm-0-0-7124]). Moreover, SSRI can inhibit the expression of mRNA in some inflammatory factors to reduce β-amyloid formation ([@b41-etm-0-0-7124]). Furthermore, we observed in the course of the study that the improvement of depression and anxiety could also assist with the improvement of the cognitive function.

Citalopram is tolerated quite well, and has been considered to be unlikely to cause drug-drug interactions and anti-adrenergic and anti-cholinergic effects, making it popular among elderly patients. However, there is evidence of QT prolongation and arrhythmia with citalopram from previous research ([@b22-etm-0-0-7124],[@b42-etm-0-0-7124],[@b43-etm-0-0-7124]). QTc interval prolongations were observed in two participants who were treated by 30 mg citalopram each day in this study. This result is in accordance with the advisory given by USA FDA and citalopram\'s current prescribing information. For patients \>60 years of age, a maximum daily dose of 20 mg of citalopram was provided by current prescribing information taking the substantially higher exposures, decreased clearance, and prolonged cardiac repolarization potential into consideration. The efficacy and adverse reaction of different doses of citalopram could not be analyzed thoroughly due to the limited number of patients. QTc interval prolongation carries clinical concern and more attention should be paid when prescribing citalopram for the elderly.

Limitations in this study can be summarized as follows: i) the number of samples was relatively small; ii) this was not a multicenter study; iii) the effect of memantine combined with citalopram on BPSD in non-Alzheimer disease forms of dementia has not been clarified; iv) the effects of different doses of citalopram on cognitive and BPSD were not analyzed; v) more comprehensive assessment of cognitive function has not been used in the study. We will design further studies considering these limitations to fully determine the efficacy, safety and tolerability of memantine combined with citalopram.

The outcomes of this clinical trial support that memantine combined with citalopram can more effectively improve cognitive function, reduce behavioral and psychological symptoms, especially agitation, apathy, dysphoria, as well as anxiety and caregiver distress in patients who have moderate AD. Cardiac adverse effects of citalopram are not common when the dose is \<30 mg/day, which does not limit its practical application. Thus, citalopram has shown potential efficacy in adjunctive therapy of AD patients with BPSD.
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###### 

Demographic, clinical features and assessment results of patients (n, mean ± SD).

  Variables                                      Study group    Control group   P-value
  ---------------------------------------------- -------------- --------------- ---------
  Sample size (n)                                40             40              
  Sex (males/females)                            16/24          17/23           0.820
  Age (years)                                    71.00±3.479    71.10±3.720     0.901
  Education (years)                              6.10±3.967     6.45±4.032      0.697
  MMSE score                                     15.10±1.945    14.80±1.964     0.494
  NPI score                                                                     
    Total score                                  34.92±10.388   34.38±8.755     0.799
    Delusions subscore                           5.83±2.806     6.00±2.160      0.713
    Hallucinations score                         0.43±1.130     0.40±1.277      0.926
    Agitation/aggression subscore                6.78±1.888     6.68±2.141      0.825
    Dysphoria subscore                           3.88±2.102     3.78±2.281      0.839
    Anxiety subscore                             3.83±2.395     3.28±2.309      0.299
    Euphoria subscore                            1.05±2.396     0.90±2.205      0.772
    Apathy subscore                              3.33±2.165     3.40±2.447      0.885
    Disinhibition subscore                       1.02±2.391     1.15±2.507      0.820
    Irritability/lability                        4.13±2.719     5.08±2.596      0.114
    Aberrant motor activity subscore             1.55±2.375     1.27±2.375      0.606
    Night-time behavioral disturbance subscore   1.50±2.810     1.45±2.631      0.935
    Appetite and eating abnormalities subscore   1.63±2.826     1.15±2.381      0.419
    Caregiver distress total score               16.10±4.313    14.88±3.596     0.172

MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.

###### 

Change of MMSE and NPI score after treatment (n, mean ± SD).

  Variables                                                Study group                                                Control group                                              P-value
  -------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------
  Sample size (n)                                          39                                                         39                                                         
  MMSE score at 12 weeks                                                                                                                                                         
    MMSE score                                             15.77±1.898                                                14.95±2.102                                                
    Change of MMSE score                                   0.67±0.772^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.18±0.644                                                 0.003^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
  NPI score at 12 weeks                                                                                                                                                          
    NPI total score                                        28.00±9.995                                                31.23±7.005                                                
    Change of NPI total score                              6.95±3.000^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   3.38±2.278^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   \<0.001^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
    Delusions subscore                                     5.69±1.749                                                 5.77±1.980                                                 
    Change of delusions subscore                           0.08±0.270                                                 0.05±0.223                                                 0.649
    Hallucinations score                                   0.36±0.986                                                 0.31±0.950                                                 
    Change of hallucinations score                         0.08±0.354                                                 0.10±0.447                                                 0.780
    Agitation/aggression subscore                          4.03±1.460                                                 4.67±1.782                                                 
    Change of agitation/aggression subscore                2.77±1.224^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   2.03±0.959^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.004^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
    Dysphoria subscore                                     2.64±1.739                                                 3.49±2.304                                                 
    Change of dysphoria subscore                           1.18±0.997^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.13±0.409                                                 \<0.001^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
    Anxiety subscore                                       2.44±1.759                                                 3.28±2.339                                                 
    Change of anxiety subscore                             1.33±1.177^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.08±0.270                                                 \<0.001^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
    Euphoria subscore                                      1.03±2.334                                                 0.85±2.084                                                 
    Change of euphoria subscore                            0.05±0.320                                                 0.08±0.354                                                 0.738
    Apathy subscore                                        2.79±2.041                                                 3.36±2.401                                                 
    Change of apathy subscore                              0.62±0.877^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.13±0.409                                                 0.002^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^
    Disinhibition subscore                                 0.87±2.041                                                 1.03±2.194                                                 
    Change of disinhibition subscore                       0.18±0.556                                                 0.15±0.489                                                 0.829
    Irritability/lability subscore                         3.90±2.624                                                 4.77±2.311                                                 
    Change of irritability/lability subscore               0.23±0.583^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.28±0.724^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.731
    Aberrant motor activity subscore                       1.38±2.208                                                 1.23±2.230                                                 
    Change of aberrant motor activity subscore             0.10±0.447                                                 0.08±0.354                                                 0.780
    Night-time behavioral disturbance subscore             1.28±2.449                                                 1.26±2.268                                                 
    Change of night-time behavioral disturbance subscore   0.26±0.637^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.23±0.583^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   0.853
    Appetite and eating abnormalities subscore             1.59±2.721                                                 1.13±2.319                                                 
    Change of appetite and eating abnormalities subscore   0.08±0.354                                                 0.05±0.320                                                 0.738
    Caregiver distress total score                         12.85±4.209                                                13.62±3.209                                                
    Change of caregiver distress total score               3.18±1.571^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   1.59±1.352^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^   \<0.001^[a](#tfn2-etm-0-0-7124){ref-type="table-fn"}^

Statistically significant difference (P\<0.05). MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.

###### 

Number of adverse events in the study and control group.

  Adverse event   Study group n (%)   Control group n (%)   P-value
  --------------- ------------------- --------------------- ---------
  Headache        3 (7.5)             4 (10)                0.692
  Nausea          2 (5)               4 (10)                0.396
  Dizziness       2 (5)               3 (7.5)               0.644
  Fatigue         1 (2.5)             2 (5)                 0.556

[^1]: Contributed equally
